Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update
Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...
Morningstar14d
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update
GS-6791 (previously NX-0479): GS-6791 is a potent, selective, oral degrader of IRAK4. Degradation of IRAK4 by GS-6791 has potential applications in the treatment of rheumatoid arthritis and other ...
The Daily Beast20d
Anti-Immigrant KKK Posters Cropped Up in Kentucky on Inauguration Day
Got a tip? Send it to The Daily Beast here. ADVERTISEMENT ADVERTISEMENT ...
India Today22d
Chhaava: Vicky Kaushal looks fierce in new posters, trailer to release on January 22
On Monday, the makers of Vicky Kaushal's Chhaava released four new powerful avatars of the actor from the film. Alongside the posters, they also announced that the trailer of the film will release on ...
clinicaltrialsarena27d
Sanofi to increase competition in atopic dermatitis market after Dupixent success
Within the AD field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration with Kymera Therapeutics. The drug is currently in Phase II clinical trials and may play an ...